Previous close | 8.30 |
Open | 8.42 |
Bid | 8.51 x 100 |
Ask | 8.60 x 100 |
Day's range | 8.29 - 8.74 |
52-week range | 8.01 - 21.70 |
Volume | |
Avg. volume | 233,306 |
Market cap | 221.103M |
Beta (5Y monthly) | 1.29 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.40 |
Earnings date | 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 25.80 |
VALENCIA, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its first quarter 2024 financial results after the close of the U.S. financial markets on Monday, May 13, 2024. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Tuesday, May 14, 2024, at 6:30 a
VALENCIA, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced an update to its expected commercial revenue for the first quarter of 2024 and reaffirmed expectations for full-year 2024 revenue at the lower end of the previously provided guidance of US$78.5 million to US$84.5 million. For the quarter ended March 31,
While not a mind-blowing move, it is good to see that the AVITA Medical, Inc. ( NASDAQ:RCEL ) share price has gained...